Category Archives: Stem Cell Treatment


Treatment of AML in Older Patients Almost At ‘The Holy Grail’ – Curetoday.com

Recent drug approvals in the acute myeloid leukemia (AML) space have allowed older patients with the disease to continue receiving less intensive therapies than their younger counterparts, while also providing them with improved outcomes.

Were almost at the holy grail where (we) have lower intensity therapy thats well tolerated, but that the response rates are higher, said Dr. Tapan Kadia, an associate professor in the department of leukemia at The University of Texas MD Anderson Cancer Center in Houston, in an interview with CURE. Theyre not reaching (the 85% seen) with intensive chemotherapy, but (theyre) much better.

Kadia recently presented on the topic of treating older patients with AML during CUREs Educated Patient Leukemia Summit and highlighted how its vastly different than treating younger, and more fit patients.

He explained how the incidence of AML increases as a person gets older and that 60% of people who receive a diagnosis are aged older than 60 years.

Because more than half of the patient population with AML is aged older than 60 years, Kadia stressed that treatment approaches should be individualized for each patient. And, he said, factors such as their comorbidities, age, ability to tolerate chemotherapy and whether they could be candidate for a stem cell or bone marrow transplant in the future should play a role in selecting which treatment option they receive.

The major point to get across (is) to characterize a leukemia and to provide a therapy thats best for that patient long term, he said.

Although younger patients with the disease tend to receive more intensive chemotherapy regimens, it is tougher to administer those same regimens to older patients because it can wipe out their blood cell counts and it is difficult to deliver in a safe way, Kadia explained. In addition, older patients are more likely to have comorbidities such as heart disease, diabetes or COPD, which must also be managed in an intensive chemotherapy setting.

In years past, the lower intensity therapies were more tolerable, but they were not associated with great response rates. However, with the recent Food and Drug Administration approval of Venclexta (venetoclax), overall response rates increased to 65% and complete remission rates now are in the range of 35% to 40% when combined with drugs such as decitabine or azacitidine), Kadia explained. He said that these regimens are associated with very, very good outcomes with a median survival of 14.5 months, and the older patients tolerate it better.

Typically, patients who have AML and are in remission undergo a stem cell transplant or bone barrow transplant. However, for an older patient, a transplant is too risky. Regardless, Kadia noted that their remission should be maintained. Maintenance therapy is then used in this population to keep their disease in remission. Maintenance therapy usually consists of low-intensity, long-term treatment that can maintain the diseases response and help prevent the leukemia from returning.

What most people need to realize is that most subsets of AML are incurable, he said. That means (the disease) will typically try to come back if not treated aggressively and long term. And so this maintenance therapy allows people to maintain remission once they have achieved it.

We have really had a revolution in the treatment of AML, where previously we only had two or three drugs to treat AML and many people got intensive chemotherapy, Kadia concluded. We are fortunate now to live in an era where we have nine new drugs approved just in the last five years.

For more news on cancer updates, research and education, dont forget tosubscribe to CUREs newsletters here.

Read the rest here:
Treatment of AML in Older Patients Almost At 'The Holy Grail' - Curetoday.com

Animal Stem Cell Therapy Market Identify Key Drivers, Trends, Latest Innovations, Business Senario, Demand With Outlook by 2026 – The Market Writeuo -…

According to a new research report titled Animal Stem Cell Therapy Market Global Industry Perspective, Comprehensive Analysis And Forecast by 2021 2026

This has brought along several changes in This report also covers the impact of COVID-19 on the global market.

The report provides revenue forecasts for global, regional and country levels. It also provides comprehensive coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. For the purpose of research, The Report has segmented global Animal Stem Cell Therapy market on the basis of types, technology and region

Get a Sample PDF copy of Animal Stem Cell Therapy Market @ https://www.reportsinsights.com/sample/493406

Key Competitors of the Global Animal Stem Cell Therapy Market are: MediVet Biologic, VETSTEM BIOPHARMA, J-ARM, Celavet, Magellan Stem Cells, U.S. Stem Cell, Cells Power Japan, ANIMAL CELL THERAPIES, Animal Care Stem, Cell Therapy Sciences, VetCell Therapeutics, Animacel, Aratana Therapeutics

The Global Animal Stem Cell Therapy Market Research Report is a comprehensive and informative study on the current state of the Global Animal Stem Cell Therapy Market industry with emphasis on the global industry. The report presents key statistics on the market status of the global Animal Stem Cell Therapy market manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.

To get this report at a profitable rate.: https://www.reportsinsights.com/discount/493406

Regional Animal Stem Cell Therapy Market (Regional Output, Demand & Forecast by Countries):- North America (United States, Canada, Mexico) South America ( Brazil, Argentina, Ecuador, Chile) Asia Pacific (China, Japan, India, Korea) Europe (Germany, UK, France, Italy) Middle East Africa (Egypt, Turkey, Saudi Arabia, Iran) And More.

The research report studies the past, present, and future performance of the global market. The report further analyzes the present competitive scenario, prevalent business models, and the likely advancements in offerings by significant players in the coming years.

Key Questions answered by the Report

Access full Report Description, TOC, Table of Figure, Chart, etc. @ https://www.reportsinsights.com/industry-forecast/animal-stem-cell-therapy-market-statistics-493406

About US:

Reports Insights is the leading research industry that offers contextual and data-centric research services to its customers across the globe. The firm assists its clients to strategize business policies and accomplish sustainable growth in their respective market domain. The industry provides consulting services, syndicated research reports, and customized research reports.

Contact US:

Email:[emailprotected]

Sales:[emailprotected]

Original post:
Animal Stem Cell Therapy Market Identify Key Drivers, Trends, Latest Innovations, Business Senario, Demand With Outlook by 2026 - The Market Writeuo -...

8 Tips for Coping With a Diagnosis of PPMS – Everyday Health

Primary-progressive multiple sclerosis (PPMS) is known for being an especially debilitating form of multiple sclerosis in which disability steadily worsens over time, sometimes quickly. This form of MS affects about 10 to 15 percent of people diagnosed with multiple sclerosis.

Typically, people with PPMS do not have distinct periods of relapse or remission, as is the case with more common form of MS, relapsing-remitting MS.

While there are approaches for controlling the symptoms of PPMS, treatments for the condition are limited: Only one medication, Ocrevus (ocrelizumab), has been approved by the U.S. Food and Drug Administration (FDA) for slowing the progression of PPMS.

RELATED: 10 Essential Facts About Primary-Progressive MS

Because PPMS is progressive and often disabling, receiving a diagnosis can be traumatic.

Beth Broun, a New York City native who now lives upstate, received her diagnosis 10 years ago. The 56-year-old first noticed something was wrong when her left leg began feeling weak, and she started tripping over her left foot.

My husband and I were walking on the Upper West Side [of Manhattan], and my left foot completely flopped, Broun says.

Her primary care physician sent her to a neurologist who was not an MS expert. He advised her to get physical therapy, but after six months nothing had changed.

It took her two years before she consulted another neurologist who ordered a brain scan and spotted the tell-tale signs of MS.

RELATED: Advances in Diagnosing Multiple Sclerosis

I freaked out, says Broun. She called her husband and told him the news and then did what she thought was the next most essential thing: I went to Bergdorf Goodman, and I bought a $3,500 handbag, because thats what you do when youre diagnosed.

After getting over the initial shock of the diagnosis, Broun started the gradual process of coming to terms her condition and then creating a plan to deal with the symptoms. Here are some tips that can help anyone who is newly diagnosed with PPMS.

As director of the MS Comprehensive Care Center at Stony Brook Neurosciences Institute, Patricia Coyle, MD,treats patients with PPMS and understands why a diagnosis is especially traumatic.

As you learn more about the disease, you realize that primary-progressive MS is a more significant form, where there is basically inevitable disability, says Dr. Coyle.

Coyle stresses, however that an education program is extremely important, because it can reduce fears. The more people know, the better they are able to deal with the illness and to find the information they need about therapies and disease progression that can provide them with the hope to go on and develop coping skills to live with the illness.

Coyle says that people need to know that they can clinically stabilize, sometimes for up to several years, and they can even see some improvement its in the minority, but that can occur.

Because the pace of worsening of PPMS doesnt tend to change over time, people who have it have some idea of what to expect from year to year.

Still, its important to have medical providers who can talk with you about what youre experiencing.

I think you want to have a relationship with your healthcare providers where you are free to ask any questions that you have, Coyle says.

A good starting point to find answers to commonly asked questions about PPMS is the National Multiple Sclerosis Society (NMSS). The website of the Multiple Sclerosis Association of America is another good place to find authoritative information about the various types of MS, including PPMS.

But, Broun cautions, dont automatically trust all of the advice or assertions about MS that you might read online, even when a person appears to write with great authority. Some of what she read along the way convinced her that she might go blind or lose her ability to speak. Having a medical provider who can help you sort out whats real and whats not can be a big help in these situations.

Along these lines, Coyle cautions about internet scams that promise miracle cures and prey on desperate patients.

If you read, We have stem cells that will improve your MS; you only need to pay $20,000, that's not legitimate, she says. There is no documented stem cell treatment for MS at this point in time.

Having PPMS doesnt mean you have to stop working. Its symptoms and progression are unique to each individual, so the illness doesnt have to mean an end to career.

In an article for Roche Pharmaceuticals, professor Jrme de Seze, PhD, the department head of the Neurology and Clinical Investigation Centre at the University of Strasbourg in France, wrote that most PPMS patients he deals with are keen to keep working.

Coyle emphasizes that a diagnosis doesnt have to be a career-ender. While this is a more severe form of MS, people can still continue to function for prolonged periods of time, she says.

Because some of the symptoms such as fatigue and cognitive impairment may limit ones ability to work, an individual may seek to work part-time.

The NMSS provides a legal guide for people with MS that addresses many workplace-related questions, such as "Am I obligated to tell my employer about my MS diagnosis?" and "Can I be let go from my job because of my MS?"

Work situations are always going to vary, but Coyle notes that some employers may be sympathetic.

An informed employer could actually be potentially very helpful with regard to accommodations, she says.

RELATED: 6 Top Tech Recommendations for Primary-Progressive MS

Broun says that the No. 1 thing to do is to put together a trusted health support team. This can include a neurologist, primary care provider, physical therapist, and mental health professional.

In Brouns case, it took some trial and error to find an MS care provider who felt right for her. But after consulting with different specialists, Broun found that Saud Sadiq, MD, a neurologist at the Tisch MS Research Center in New York City, provides guidance and treatment options that she believes in.

RELATED: Shared Decision-Making for MS Treatment

A mental health professional can be a key member of your health support team.

Its not uncommon for patients early in diagnosis to go through an adjustment period of anxiety and some depression when they hear they have MS, says Laura Safar, MD, an assistant professor of psychiatry at Brigham and Womens Hospital in Boston and a psychiatrist who treats psychiatric disorders among people with multiple sclerosis. Patients may have fears about their prognosis, and questions about what their progression will be like.

Individuals cope in different ways, Dr. Safar says. Some of them can be very proactive and want to learn about everything they can do to improve their health. Others can be overwhelmed, and avoid dealing with the diagnosis and treatment.

Safar says that it can be helpful for clinicians to observe how different patients cope with their illness to understand what type of support or interventions they need in addition to educating them about the diagnosis and next steps for treatment.

Doctors and patients alike should be aware that PPMS can affect a persons cognition, or their ability to think, remember, and perform other mental tasks.

Depending on a persons needs, appropriate interventions may include a neuropsychological evaluation to assess cognition, or a referral to a psychotherapist or psychiatrist to focus on emotional and coping issues. Mental health therapy may involve both talking through problems and taking antidepressants.

Rehabilitation therapies including physical, occupational, and cognitive rehabilitation can be tools to sustain and improve a patient's cognitive and functional abilities.

From a psychological perspective, rehabilitationstrategies, when combined with disease-modifyingtreatment, can assist in providing a sense of mastery over their illness, she says.

Ultimately, Safar says that her goal is to help individuals figure out how do I make this illness a part of my life, but not let it define the whole of who I am and what my life is about.

Safar notes that ideally, friends and family members should be part of the support network a person with MS relies on.

I want to make sure that people are not isolated and not alone, she says. So I find out if they have friends or family they can talk to about their diagnosis.

Safar recognizes that for some it can be difficult to even share they are ill. They are concerned that a partner may not be supportive or may turn away. Or they fear that they will cause too much worry among family members. They want to protect their loved ones and their relationships, she says.

Because she firmly believes that patients should not take this on alone, she advises some to take gradual steps toward disclosing information about the diagnosis and see how people close to them react.

RELATED: How MS Contributes to Isolation and What You Can Do to Stay Connected

In addition to seeking emotional support from friends and family, people with PPMS may also want to connect with one or more online groups.

Through participating in several MS groups on Facebook, Broun developed a deep friendship with another person with PPMS who lives in the Netherlands, and they each push the other to be proactive about their illness.

We say were going to fight each other; were going to outrun each other, she jokes. Hes a force.

For those looking for online support and connection, Broun suggests exploring Moodify, the PPMS Facebook page, as well as the International Progressive MS Alliance.

While looking after your mental state is vital to living with PPMS, so is doing your best to maintain good physical health. Broun gets around nowadays with a walker. She says its brutal to see herself in the mirror that way, but without exercise, she might not even be walking.

Exercise is the No. 1 thing to me, says Broun.

When she was first diagnosed, Broun began working with a physical therapist to maintain mobility and function. She started doing leg presses and walking on an uphill treadmill for 10 minutes to build strength in her glutes, hip flexors, and hamstrings.

Currently, she meets with a personal trainer two times a week to work on her muscle strength and balance, which she describes as incredibly weak. Because Broun has foot drop (difficulty lifting the front part of her foot), she does special exercises to keep her foot up.

My favorite exercise, which may not be specific forMS but makes me feel dynamite, is riding a spin bike, says Broun. You would never know I have a MS when Im riding it, but as soon as I get off I can barely walk. I love the confidence and ego boost I get from it.

On her visits with Dr. Sadiq, she also works with a new therapist on a special robotic machine, which helps someone like me use muscles I havent used in years.

To get started with exercise on your own, the Multiple Sclerosis Trustprovides a series of strength, stretching, balance, and breathing exercises for people with MS to explore and use to build their own routine for physical activity.

Following a healthy diet is also important for maintaining strength and stamina. For Broun, this means sticking to a Mediterranean-type diet, primarily consisting of organic proteins and vegetables.

At the end of the day, says Broun, I can control my exercising, and I can control what I can eat to feel good otherwise, MS is an animal, and its going to take over my body.

Coyle recommends exploring the many MS apps on the market for tracking symptoms and other purposes.

Apps have a number of different functions they can help track activities, track what youre doing in terms of exercise, and enable you to easily look up information related to MS, she says.

The Multiple Sclerosis Clinical Care App, for example, contains current information on the diagnosis, classification, and management of multiple sclerosis (MS), concisely presented for use at the point of care.

Several appsare available that allow you to track symptoms, notes TeamScope. My MS Manager, created and supported by the Multiple Sclerosis Association of America, is one such example.

The National MS Society recommends Happy the App, a 24/7 phone-based emotional support service via mobile app that connects individuals experiencing everyday stresses, struggles, anxiety, or loneliness with exceptionally compassionate listeners.

Read the original post:
8 Tips for Coping With a Diagnosis of PPMS - Everyday Health

More positive results from CRISPR trial for sickle cell and thalassaemia – BioNews

16 August 2021

A genome editing-based gene therapy forblood diseasessickle cell disease andbeta-thalassaemia continues to be effective more than two years after treatment.

The clinical trial for the therapy, named CTX001, previously reported good preliminary results (see BioNews 1052) and new data was presented at the European Haematology Association 2021 Virtual Congress.

'We are hearing that it is life-changing.' said Professor Stephan Grupp from the Cell and Gene Therapy Laboratory at Children's Hospital of Philadelphia, one of the researchers collaborating on the trial.

Patients with sickle cell disease or beta-thalassaemia carry a mutation in a single gene that causes problems in an essential blood molecule called haemoglobin. Patients usually require lifelong blood transfusions, sometimes stem cell transplants, as well as ongoing pain management. Sickle cell disease can also impact reproductive health in women (see BioNews 1105).

This clinical trial involved taking a patient's own blood stem cells, called hematopoietic stem cells, and editing them outside the body.CRISPR/Cas9 genome editing wasused to reactivatea different haemoglobin gene that is usually only expressed in the fetus and is switched off at birth. The editedstem cells were transplanted back into thepatients, who started producing fetal haemoglobin,replacingthe nonfunctional haemoglobin that causeddisease symptoms.

'The data presented today in 22 patients are impressive in both the consistency and durability of effect. These results add to the growing body of evidence that CTX001 may hold the promise for a one-time functional cure for sickle cell disease and beta-thalassemia.' said Dr Reshma Kewalramani, CEO of Vertex Pharmaceuticals in Boston, Massachusetts, who developed the treatment in partnership with CRISPR Therapeutics from Zug, Switzerland.

Aftertwo years post-gene therapy, the sickle cell disease patients were reported to be free of vaso-occlusive crises; a painful organ injury occurring when blood cells cause blockages, common to sickle cell disease patients. None of the beta-thalassaemia patients has required any further blood transfusions as all have started producing functional levels of fetal haemoglobin in their blood.

'The evidence so far indicates that it is durable in the time frame we've seen, and we just have to continue to follow the patients' said Professor Grupp.

See original here:
More positive results from CRISPR trial for sickle cell and thalassaemia - BioNews

Belumosudil Granted Full Approval for Treatment of Chronic GVHD by FDA – Cancer Network

The ROCK-2targeting agent belumosudil is now approved by the FDA to treat adult and pediatric patients with chronic graft-versus-host disease after 2 prior lines of therapy.

The agent belumosudil (Rezurock) may now be used to treat adult and pediatric patients 12 years of age and older with chronic graft-versus-host disease (cGVHD) who have been unsuccessfully treated with 2 prior lines of therapy, according to the company responsible for the agent, Kadmon Holdings, Inc.1

This approval follows a priority review for the new drug application (NDA) that was granted back in November for the Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor.2 The submission of the NDA was supported by data from the phase 2 ROCKstar (KD025-213) trial (NCT03640481) of belumosudil at 200 mg daily or twice daily in patients with previously treated cGVHD.

REZUROCK represents a new treatment paradigm for thousands of cGVHD patients, including those with difficult-to-treat manifestations like fibrosis, Corey Cutler, MD, MPH, FRCPC, Associate Professor of Medicine at Harvard Medical School and Medical Director of the Adult Stem Cell Transplantation Program at the Dana-Farber Cancer Institute, said in a press release. REZUROCK has shown robust and durable responses across the spectrum of cGVHD and is safe and well tolerated, allowing patients to stay on therapy and achieve meaningful benefit from treatment.

The randomized, open-label, multicenter, pivotal trial treated 65 patients at the once-daily dose, with a median time from diagnosis of 25.3 months. Of those, 48% of patients had at least 4 organs involved, 78% were refractory to their last therapy, and the median number of prior therapies was 3.

The objective response rate in the once-daily dose group was 75% (95% CI, 63%-85%) through cycle 7, day 1, comprised of 6% complete responses and 69% partial responses. The median response duration was 1.9 months.

The median time to first response was 1.8 months and 62% of patients did not require any new systemic therapy for 12 months following belumosudil treatment.

The agent appeared to be well tolerated and was consistent with the known profile of corticosteroids and/or other immunosuppressants in this setting.

Patients receiving REZUROCK reported significant improvements in cGVHD symptoms, showing that not only did treatment result in organ responses, but it also made people feel better. This is so important for a chronic disease with a high symptom burden, Stephanie Lee, MD, MPH, Professor at the Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine and Research Director of the Long-Term Follow-Up Program at Fred Hutchinson, said in a press release.

References

1. U.S. FDA Grants Full Approval of REZUROCK(TM) (belumosudil) for the Treatment of Patients with Chronic Graft-Versus-Host Disease (cGVHD). Kadmon Holdings, Inc. July 16, 2021. July 16, 2021. https://finance.yahoo.com/news/u-fda-grants-full-approval-182000289.html

2. Kadmon Announces FDA Acceptance of NDA for Belumosudil in Patients With Chronic Graft-Versus-Host Disease. Kadmon Holdings, Inc. November 30, 2020. July 16, 2021. https://investors.kadmon.com/news-releases/news-release-details/kadmon-announces-fda-acceptance-nda-belumosudil-patients-chronic

View post:
Belumosudil Granted Full Approval for Treatment of Chronic GVHD by FDA - Cancer Network

Dr. Martin on the Role of Maintenance Therapy With Rituximab in MCL July 15th 2021 Peter – OncLive

Peter Martin, MD, discusses the role of maintenance therapy with rituximab in mantle cell lymphoma.

Peter Martin, MD, chief of the Lymphoma Program at the Meyer Cancer Center and an associate professor of medicine at Weill Cornell Medicine, discusses the role of maintenance therapy with rituximab (Rituxan) in mantle cell lymphoma (MCL).

Improved overall survival has been demonstrated with rituximab maintenance following R-CHOPbased therapy, as well as following autologous stem cell transplant, says Martin. However, the role of rituximab maintenance after bendamustine-based therapy had not been fully realized, Martin adds.

During the 2021 ASCO Annual Meeting, findings from a retrospective, real-world analysis demonstrated that bendamustine/rituximab was the most used first-line therapy for patients with MCL in community-based practices in the United States. Additionally, the data suggested that rituximab maintenance following treatment yielded superior outcomes in patients, Martin says. As such, all patients should receive rituximab maintenance after bendamustine-based induction therapy unless they have contraindications, concludes Martin.

More:
Dr. Martin on the Role of Maintenance Therapy With Rituximab in MCL July 15th 2021 Peter - OncLive

Stemson Therapeutics Secures $15M Series A Funding to Cure Hair Loss – Business Wire

SAN DIEGO--(BUSINESS WIRE)--Stemson Therapeutics announced today the closing of a DCVC Bio-led $15 million Series A financing to advance development of Stemsons proprietary therapeutic solution to cure hair loss. Genoa Ventures, AbbVie Ventures and other investors join in supporting Stemsons efforts to restore human hair growth with a novel cell regeneration technology using the patients own cells to generate new hair follicles.

In addition, Kiersten Stead, Ph.D., Co-Managing Partner at DCVC Bio and Jenny Rooke, Ph.D., Managing Director at Genoa Ventures will join Stemsons Executive Chairman Matt Posard and Chief Executive Officer and co-founder Geoff Hamilton on the board of directors. Dr. Stead invests in early-stage companies that build novel deep tech businesses in the life sciences. Stead received a Ph.D. in Molecular Biology & Genetics and an MBA in finance from the University of Alberta. Dr. Rooke is founder and Managing Director at Genoa Ventures where she specializes in early-stage companies innovating at the convergence of technology and biology. Rooke received a Ph.D. in Genetics from Yale University and a degree in physics from the Georgia Institute of Technology.

We are excited and honored to welcome DCVC Bio and a fantastic syndicate of investors to the Stemson team. The Series A funding will help us optimize our solution for human skin structure and environment so we can go into our first human clinical trial with high confidence for a positive outcome. We have the technical and biological building blocks to successfully address hair loss that overcomes failures of past therapies, said Hamilton. The addition of key venture capital investors DCVC Bio, Genoa Ventures and AbbVie Ventures broadens and strengthens our investor base. DCVC Bio and Genoa Ventures are successful early-stage development investors, and I am pleased to welcome Dr. Stead and Dr. Rooke, our newest board members, to the team. In addition, the AbbVie Venture investment comes on the heels of an initial seed investment from Allergan Aesthetics in 2020, and the continued industry interest in our technology is encouraging.

Globally, hundreds of millions of men and women suffer from various forms of hair loss. Though there are many possible causes of hair loss, including chemotherapy, autoimmune disease, scarring, and genetics, all can result in a loss of self-esteem and cause depression, anxiety and other mental health disruption for those affected. The hair restoration market is expected to exceed $13.6 billion by 2028, and no solution today is capable of generating an unlimited new supply of healthy follicles for patients in need.

Almost 30 years have passed since the last FDA-approved hair loss treatment, yet millions still suffer the physical and mental impact of losing their hair each year, stated Dr. Stead. Stemsons novel stem cell engineering platform has the potential to cure hair loss once and for all, treating not only the physical symptoms of this complex problem, but the mental burden as well.

"The team at Genoa is impressed with Stemsons vision to blend biology and technology and apply it beyond traditional biotech," added Dr. Rooke. "By combining exciting advancements in iPSCs with novel technologies in materials and data sciences, Stemson exemplifies the kind of chimeric teams Genoa seeks to support on their journey to become a category-defining company."

The Series A financing brings the total funding raised to date to $22.5 million and allows Stemson to further the next stage of research and development of its cell engineering platform, where is it being combined with bioengineered material and robotic delivery as a novel solution for natural hair replacement. Currently, Stemsons research and development efforts are focused on developing an optimized solution for human skin structure environment in larger animal models. Stemsons Induced Pluripotent Stem Cell (iPSC) based technology is capable of producing the cell types required to initiate hair follicle growth and have been successfully tested in small animal models.

About Cell Regeneration Technology

Human Induced Pluripotent Stem Cells (iPSC) have the unique capability to replicate indefinitely and give rise to all cell types of the human body, including the cell types required for repair. iPSC-based technology is capable of producing the cell types required to initiate hair follicle growth. As a new therapeutic platform, iPSCs represent an emerging area of regenerative cell therapy. Stemson is one of a growing number of companies at the forefront in developing iPSC-based treatments.

About DCVC Bio

For over twenty years, DCVC and its principals have backed brilliant entrepreneurs applying Deep Tech, from the earliest stage and beyond, to pragmatically and cost-effectively tackle previously unsolvable problems in nearly every industry. DCVC Bio specializes in supporting life sciences platform companies at the intersections of engineering and therapeutics, industrial biotechnology and agriculture. For more information, please visit https://www.dcvc.com/companies.html#dcvc-bio

About Genoa Ventures

Genoa Ventures invests in early-stage companies working at the convergence of biology & technology to accelerate the pace of innovation, transform industries, and solve some of the most fundamental challenges to life. Genoa, identifies opportunities early and focuses its investments and expertise to empower the next great category-defining companies. The Genoa team has a unique chimeric blend of experience from scientific research and discovery to executive management in the life sciences and technologies sectors. The team applies this diverse experience to provide expert guidance to its companies and stellar returns to its investors.

About AbbVie Ventures

AbbVie Ventures is the corporate venture capital group of AbbVie. We are a strategic investor, investing exclusively in novel, potentially transformational science aligned with AbbVie's core R&D interests. We measure success primarily by the extent to which our investments foster innovation with potential to transform the lives of patients that AbbVie serves. AbbVie Ventures enables its portfolio companies with both funding as well as access to AbbVie's internal network of experts across all phases of drug development, from drug discovery through commercialization. For more information, please visit http://www.abbvie.com/ventures

About Stemson Therapeutics

Stemson Therapeutics is a pre-clinical stage cell therapy company founded in 2018 with a mission to cure hair loss by leveraging the regenerative power of Induced Pluripotent Stem Cells. Based on the breakthrough innovation by Stemson Therapeutics co-founder, Dr. Alexey Terskikh, Stemson uses iPSC to regenerate the critical cells required to grow hair and which are damaged or depleted in patients suffering from hair loss. The iPSC-derived cells are used to grow de novo hair follicles, offering a new supply of hair to treat people suffering from various forms of Alopecia. Today, there are no available treatments capable of growing new hair follicles. Stemsons world class team of scientists, advisors and collaborators are passionate about delivering a scientifically based, clinically tested cure for hair loss to the millions of hair loss sufferers who seek help for their hair loss condition. Stemson Therapeutics is headquartered in San Diego, CA. For more information, please visit http://www.stemson.com.

See the article here:
Stemson Therapeutics Secures $15M Series A Funding to Cure Hair Loss - Business Wire

FDA tells Magenta to pump the brakes on blood cancer trial before it starts to develop new dosing test – FierceBiotech

Magenta Therapeutics has been asked by the FDA to pump the brakes on a trial for its blood cancer med before it even got started.

The FDA would like the biotech to develop an additional test to inform dose escalation and safety monitoring in the proposed phase 1/2 clinical trial, according to a Wednesday release.Magenta submitted a regulatory filing last month for the trial to test MGTA-117 in patients with the blood cancersacute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

Magenta said the additional test is the only request from the clinical hold letter. The agency did not institute any stops related to toxicology or manufacturing of the drug.

The exact date the study wasexpected to commence was not disclosed, but Magenta did report during first quarter earnings earlier this year that the company "expects to assess initial safety and pharmacokinetic data internally in the fourth quarter of 2021."

RELATED:Magenta stem cell transplant drug seems to work, but is it safe?

Work to develop the test has already begun,and Magenta does not anticipate technical challenges in the process, said President and CEO Jason Gardner in a statement. Magenta will work with the FDA to determine the new test's application for dose escalation, the company said.

"We expect to request a Type A meeting in the coming weeks and, if successful in resolving this remaining issue, we would anticipate opening the study in Q4 2021," Gardner said.

The antibody-drug conjugate is meant to selectively deplete hematopoietic stem cells from patients before transplant or stem cell-based gene therapy, which would reduce the need for high-dose or high-intensity chemotherapies, Magenta said.

MGTA-117 is initially being tested in AML and MDS, pending the FDA's future reassessment of the proposed clinical trial. Magenta believes the therapy has potential for applications across other blood cancers, sickle cell disease, inherited metabolic disorders and other areas. The CD117 receptortargeted by the drugis expressed on the cell surface of hematopoietic stem cells and leukemia cells.

RELATED:Aptinyx, Magenta lead biotech IPO flurry ahead of summer lull

In May 2020, Magenta linkedarms with Avrobio to evaluate the potential use of the drug to condition patients before receiving Avrobio's investigational lentiviral gene therapies. And, last June, the biotech teamedup with Beam Therapeutics on a research and clinical collaboration to assess the potential use of the drug to condition patients with sickle cell disease and beta-thalassemia who are taking Beam's base editing therapies.

The company had more than $200 million in cash at the end of the second quarter, which is expected to provide a runway to execute on existing plans.Magenta shares were down more than 7%, to $8.25 apiece, as of 10:30 a.m. ET.

The rest is here:
FDA tells Magenta to pump the brakes on blood cancer trial before it starts to develop new dosing test - FierceBiotech

Events planned to support 5-year-old’s cancer treatments – The Augusta Chronicle

A blood drive and benefit ride to support 5-year-old Mason Burnettes cancer treatments is being held this week in Glascock County.

In January, just a few days after his fifth birthday, Mason Burnette was diagnosed with Stage IV high-riskNeuroblastoma, a form of childhood cancer.

Mason received more than10 platelet and blood transfusions. He successfully underwent an adrenalectomy after five rounds of chemotherapy treatments. Mason is expected to soon receive a stem cell transplant. His family is hosting a blood drive in honor of Mason to help spread the word on just how much donating blood can affect the lives of childhood cancer patients.

The blood drive, held in conjunction with Shepeard Blood Center, is scheduled for Thursday, July 22, from 2 p.m. to 7 p.m. at 437 East Main St. in Gibson.

The benefit ride will begin at Brassell Park in Gibson July 24at 10 a.m. with the approximately 50-mile ride pulling out around 11 a.m. Organizers welcomebikes, jeeps, hot rods, and any vehicles to take part.

View post:
Events planned to support 5-year-old's cancer treatments - The Augusta Chronicle

HER2-Specific CAR T Cells Induce Early Efficacy Without Dose-Limiting Toxicities in Pediatric CNS Tumors – OncLive

The clinical evidence included high concentrations of C-X-C motif chemokine ligand 10 (CXCL10) and C-C motif chemokine ligand 2 (CCL2) in the cerebrospinal fluid (CSF) and serum samples.

This interim report supports the feasibility of generating HER2-specific CAR T cells for repeated dosing regimens and suggests that their repeated intra-CNS delivery might be well tolerated and activate a localized immune response in pediatric and young adult patients, Nicholas Alexander Vitanza, MD, an assistant professor at the Ben Towne Center for Childhood Cancer Research, and a staff member of the Cancer and Blood Disorders Center, Brain Tumor Program, Apheresis, at Seattle Childrens, and coauthors, wrote in the study publication.

Although the integration of CAR T-cell therapy has provided a novel therapeutic modality to manage multiple hematologic malignancies, the utility of CAR T cells is not fully understood for pediatric patients with CNS tumors.

HER2 offers a valid target for CAR T-cell therapy in CNS tumors because it is widely expressed on a significant proportion of biologically diverse CNS tumors such as ependymoma, glioblastoma, and medulloblastoma, as well as CNS cancer stem cells. Moreover, HER2 is not expressed on normal CNS tissue.

Monoclonal antibodies, such as trastuzumab (Herceptin), are beneficial for patients with some HER2-expressing cancers but have limited activity in CNS tumors that require a therapy that crosses the blood-brain barrier. CNS tumors also harbor less HER2 expression compared with malignancies like breast cancer.

As such, directly administering HER2-directed therapy to the tumor site could be a lucrative strategy for patients with CNS tumors.

Preclinical data demonstrated that spacer length was correlated with improved activity of HER2-specific CAR T cells. Based on this, the single-institution BrainChild-01 trial used a medium-length spacer HER2CAR to evaluate repeated locoregional delivery of HER2-specific CAR T cells for pediatric patients with recurrent or refractory CNS tumors.

Following CAR T-cell manufacturing, patients were treated in the outpatient setting for up to 6 courses. Course 1 consisted of 3 weeks of a 1 x 107 dose of CAR T cells (DL1), followed by clinical evaluation in week 4. Course 2 consisted of 1 week of DL1 treatment, 2 weeks of a 2.5 x 107 dose of CAR T cells (DL2), followed by clinical and radiographic evaluation in week 4. Courses 3 through 6 retained the same dosing schedule at the highest tolerated dosing levels, which included 2 additional tiers: 5 x 107 [DL3] and 10 x 107 [DL4].

The BrainChild-01 HER2CAR T-cell product was manufactured under a process designed to yield balanced numbers of CD4+ and CD8+ lentivirally transduced T cells exhibiting limited terminal differentiation with enrichment for the CAR+ population of cells mid-culture, Vitanza and coauthors wrote.

The initial 3 patients were required to be from 15 to 26 years old. This age group is more capable of self-reporting neurologic changes compared with a younger patient population, so they were specifically used for the initial evaluation.

The first eligible 3 patients underwent apheresis and had CAR T-cell products that were in-line with release criteria. As such, the patients were assigned to the appropriate treatment arms: repeated locoregional CNS infusion into the CNS tumor or tumor cavity (arm A; n = 1) vs repeated locoregional CNS infusion into the ventricular system (arm B; n = 2).

All patients had undergone at least 3 prior tumor-directed surgical procedures, at least 1 prior irradiation, and at least 1 prior chemotherapy regimen. Additionally, all patients had presumed pediatric biology of their tumors.

A 19-year-old female patient enrolled on arm A was diagnosed with WHO grade III localized anaplastic astrocytoma. She had 1.95 x 109 total nucleated cells manufactured and 1.87 x 109 EGFRt+ CAR T cells manufactured. She received 6 doses of treatment.

Both patients enrolled on arm B were males with WHO grade III metastatic ependymoma. The first, a 16-year-old, had 3.2 x 109 total nucleated cells manufactured, 2.97 x 109 EGFRt+ CAR T cells manufactured, and received 9 doses of treatment. The second patient, aged 26, had 2.06 x 109 total nucleated cells manufactured, 1.87 x 109 EGFRt+ CAR T cells manufactured, and received 9 doses of treatment. The latter patients product in arm B had initial failure of viability screening, but with 2 additional manufacturing attempts, enough CAR T cells were generated to complete a minimum of 2 treatment courses.

The study was designed to primarily assess feasibility, safety, and tolerability, with assessment of CAR T-cell distribution and disease response as secondary objectives.

Patients experienced post-treatment symptoms. One patient who underwent imaging experienced radiographic evidence of treatment-mediated localized CNS immune activation.

Additional results showed that the most common adverse effects (AEs) observed in all patients were headache, pain at metastatic sites of spinal cord disease, and transient worsening of a baseline neurologic deficit. Additionally, the 2 patients on arm B experienced fever within 24 hours following infusion. These AEs were deemed possibly, probably, or definitely related to CAR T-cell therapy.

Systemic C-reactive protein elevation was also noted in all patients and overlapped with the timing of headaches and/or pain.

Regarding CSF cytokines and radiographic imaging, CAR T cells were not detected in any patient at any time point following infusion in CSF via flow cytometry or in peripheral blood via quantitative polymerase chain reaction. NonCAR T cell populations of CD4+ and CD8+ T cells were detected in CSF after infusion.

Cytokines, including CXCL10, CCL2, granulocyte colonystimulating factor, granulocyte-macrophage colony-stimulating factor, IFN2, IL-10, IL12-p70, IL-15, IL1, IL-6, IL-7, and tumor necrosis factor, were detected in the CSF following infusion. One patient also had elevated VEGF.

Additional studies are planned to evaluate the relationship between target antigen density and clinical toxicity and response.

With these findings, the trial is planned to enroll the broader age cohort of patients aged 1 to 26 years. Notably, the trial will include patients with diffuse midline glioma.

Two additional studies are also planned. BrainChild-02 (NCT03638167) will deliver EGFR-specific CAR T cells to pediatric patients with recurrent or refractory EGFR-positive CNS tumors. BrainChild-03 (NCT04185038) will deliver B7-H3specific CAR T cells to pediatric patients with recurrent or refractory CNS tumors or diffuse intrinsic pontine glioma.

Gleaning the results of all 3 BrainChild studies, the investigators plan to use a multiplexed strategy to overcome tumor heterogeneity, which remains a challenge for drug development in this patient population, and antigen escape.

Ultimately, the experience of the initial three patients treated on BrainChild-01 suggests that repeated locoregional HER2-specific CAR T-cell dosing might be feasible and that correlative CSF markers might be valuable in assessing on-target CAR T-cell activity in the CNS, concluded Vitanza and coauthors.

Read the rest here:
HER2-Specific CAR T Cells Induce Early Efficacy Without Dose-Limiting Toxicities in Pediatric CNS Tumors - OncLive